TUSTIN, Calif., Nov. 15, 2011 /PRNewswire/ -- On November 14, 2011, DHS Holding Co. (DHS) issued a press release announcing it will enter into preliminary talks with Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), to discuss business opportunities that would benefit both parties. However, that press release was issued without our approval and we do not intend to have any further discussions, or enter into any business opportunities with DHS.
On today's date, our attorneys requested DHS to immediately retract the press release at issue.
The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $54,000*
*Approximate amount as of November 15, 2011Common Shares Outstanding: 746 million*
*Approximate number as of November 15, 2011.
5 billion shares authorized.Outstanding Warrants & Options: 110 million*
*Approximate number as of November 15, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predic
|SOURCE Radient Pharmaceuticals Corporation|
Copyright©2010 PR Newswire.
All rights reserved